Page 11234..»

Category Archives: ALS Treatment

Doctors Hoping Pill Form Of ALS Drug Will Be Less Intense Treatment For Patients – CBS Pittsburgh

Posted: January 31, 2020 at 9:44 am

PITTSBURGH (KDKA) Doctors are trying to make an FDA-approved drug treatment for Amyotrophic Lateral Sclerosis, or ALS, much less intense for both patients and caregivers. Continue reading

Posted in ALS Treatment | Comments Off on Doctors Hoping Pill Form Of ALS Drug Will Be Less Intense Treatment For Patients – CBS Pittsburgh

BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn – Yahoo Finance

Posted: at 9:44 am

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled 'Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors'. Allowed claims cover the method for manufacturing MSC-NTF cells (NurOwn) Continue reading

Posted in ALS Treatment | Comments Off on BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn – Yahoo Finance

GeNeuro: Cash position at December 31, 2019, Business Update and Outlook for 2020 – Business Wire

Posted: at 9:44 am

GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced its cash position at December 31, 2019, issued a business update and provided an outlook on its 2020 activities. GeNeuro continued to make significant clinical progress in 2019, said Jess Martin-Garcia, CEO of GeNeuro. The full 2-year results of our ANGEL-MS clinical trial of temelimab in multiple sclerosis, which were presented in September at the ECTRIMS 2019 congress, have confirmed the neuroprotective effect of temelimab in MS and demonstrated its potential against progression of the disease Continue reading

Posted in ALS Treatment | Comments Off on GeNeuro: Cash position at December 31, 2019, Business Update and Outlook for 2020 – Business Wire

Alexion to begin Phase 3 testing on drug to treat ALS – New Haven Register

Posted: January 18, 2020 at 12:48 am

Alexion Pharmaceuticals in New Haven Alexion Pharmaceuticals in New Haven Photo: Hearst Connecticut Media File Alexion Pharmaceuticals in New Haven Alexion Pharmaceuticals in New Haven Alexion to begin Phase 3 testing on drug to treat ALS Officials with Alexion Pharmaceuticals, which has a significant research and development presence in New Haven, announced the company will begin Phase 3 testing of one of its existing drugs for use in treating amyotrophic lateral sclerosis, also known as ALS or Lou Gehrigs disease. The study of the drug Ultomiris in treating ALS will begin before the end of March and take place over a 50-week period and evaluate 350 adults. Continue reading

Posted in ALS Treatment | Comments Off on Alexion to begin Phase 3 testing on drug to treat ALS – New Haven Register

Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease – Associated Press

Posted: at 12:48 am

-- LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinsons disease -- LRRK2 inhibitor DNL151 Phase 1 demonstrated high levels of target and pathway engagement and modulation of lysosomal biomarkers in healthy volunteers and continues in an expanded Phase 1b study in patients with Parkinsons disease -- IND submitted for DNL310 (ETV:IDS) for Hunter syndrome, Denalis first clinical submission for a large molecule therapeutic enabled by its Transport Vehicle platform technology -- CTA approved for DNL343, a small molecule activator of EIF2B for ALS and other neurodegenerative diseases -- RIPK1 inhibitor DNL747 Phase 1b trials in Alzheimers and ALS fully enrolled and open label extension in ALS ongoing with data readouts on track for mid-2020 SOUTH SAN FRANCISCO, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Continue reading

Posted in ALS Treatment | Comments Off on Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease – Associated Press

N.J. karate legend who inspired thousands loses battle with ALS – NJ.com

Posted: at 12:48 am

The pictures in the corridor, just across from the main ball room at Newarks Robert Treat Hotel, captured the martial arts greatness of Kevin Brown Thompson. A Newark native, Thompson mastered three disciplines weapons, forms and fighting and won world championships in each category, an achievement rarely attained. Hes in the Black Belt Hall of Fame, his name and accomplishments listed with legends Bruce Lee and Chuck Norris. Continue reading

Posted in ALS Treatment | Comments Off on N.J. karate legend who inspired thousands loses battle with ALS – NJ.com

Comprehensive Analysis on Prostacyclin Market based on types and application – Technology Magazine

Posted: at 12:48 am

Global Prostacyclin Market Forecast to 2025 is a new research released at Market Study Report and provides information about industry Top Key Players, Countries, Type and Application. This Prostacyclin report also states Company Profile, sales, Prostacyclin Market revenue and price, market share, market growth and gross margin by regions, Strategic recommendations for the new entrants, Market forecasts for a minimum of five years of all the mentioned segments, sub segments and the regional markets. Continue reading

Posted in ALS Treatment | Comments Off on Comprehensive Analysis on Prostacyclin Market based on types and application – Technology Magazine

Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and…

Posted: January 14, 2020 at 9:49 pm

SAN DIEGO--(BUSINESS WIRE)--Neuropore Therapies, Inc. announced today that it has successfully completed the Phase 1 clinical trial in healthy volunteers with NPT520-34. Continue reading

Posted in ALS Treatment | Comments Off on Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson’s Disease and…

List of Amyotrophic Lateral Sclerosis Medications (5 Compared …

Posted: December 23, 2019 at 7:42 am

Other names: ALS; Lou Gehrig's Disease; Motor Neurone Disease About Amyotrophic Lateral Sclerosis: A disease of the motor nerve cells in the brain and spinal cord, causing progressive loss of motor control. Continue reading

Posted in ALS Treatment | Comments Off on List of Amyotrophic Lateral Sclerosis Medications (5 Compared …

RADICAVA (edaravone)

Posted: at 7:42 am

I agree that I have read this Consent Form and by providing my personal information and clicking SIGN UP FOR UPDATES I understand and agree that Mitsubishi Tanabe Pharma America, Inc. Continue reading

Posted in ALS Treatment | Comments Off on RADICAVA (edaravone)

Page 11234..»